Amgen makes big workforce, budget cuts

The inevitable finally occurred at Amgen. Plagued by falling sales of its blockbuster anemia drugs, Amgen says it will slash about 14 percent of its workforce as part of a widespread restructuring aimed at slicing out a billion dollars in expenses. That will eliminate up to 2,600 jobs at Ventura County's biggest employer, which for years built up an impressive record of massive growth and ever-rising income. Amgen avoided getting into the messy details, but the restructuring will include the shuttering of some facilities and reductions in various operating units. Analysts generally applauded the move, which had been widely anticipated in recent days.

"The initiatives announced today respond to [our] new reality by taking account of reduced revenues and appropriately lowering costs across the company," said CEO Kevin Sharer. "We will continue to strongly support our research efforts directed at development of new medicines for grievously ill patients."

- see Amgen's announcement on the layoffs
- read the report from The Los Angeles Times 

Related Articles:
Report: Amgen looks at layoffs in restructuring. Report
Major challenges loom for Amgen. Report
Amgen in crisis? Not us, says CEO Sharer. Report
Amgen stock slips as anemia drug concerns rise. Report

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.